Navigation Links
Puzzling question in bacterial immune system answered
Date:1/29/2014

dom sites across a genome until colliding with its target, the process would be incredibly time-consuming and probably too inefficient to be effective for bacterial immunity, or as a tool for genome engineers. Our study shows that Cas9 confines its search by first looking for PAM sequences. This accelerates the rate at which the target can be located, and minimizes the time spent interrogating non-target DNA sites."

Doudna, Sternberg and their colleagues used a unique DNA curtains assay and total internal reflection fluorescence microscopy (TIRFM) to image single molecules of Cas9 in real time as they bound to and interrogated DNA. The DNA curtains technology provided unprecedented insights into the mechanism of the Cas9 target search process. Imaging results were verified using traditional bulk biochemical assays.

"We found that Cas9 interrogates DNA for a matching sequence using RNADNA base-pairing only after recognition of the PAM, which avoids accidentally targeting matching sites within the bacterium's own genome," Sternberg says. "However, even if Cas9 somehow mistakenly binds to a matching sequence on its own genome, the catalytic nuclease activity is not triggered without a PAM being present. With this mechanism of DNA interrogation, the PAM provides two redundant checkpoints that ensure that Cas9 can't mistakenly destroy its own genomic DNA."


'/>"/>

Contact: Lynn Yarris
lcyarris@lbl.gov
510-486-5375
DOE/Lawrence Berkeley National Laboratory
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Fielding questions about climate change
2. New CU-NOAA monitoring system clarifies murky atmospheric questions
3. Researchers question pulling plug on pacifiers
4. Study raises questions about use of anti-epilepsy drugs in newborns
5. Just a question of time?
6. Questionnaire completed by parents may help identify 1-year-olds at risk for autism
7. New research questions how fat influences flavor perception
8. Paddlefishs doubled genome may question theories on limb evolution
9. Chicken and egg question (and answer) for rural Uganda
10. Georgetown Lombardi researcher awarded Provocative Question grant from NCI
11. Columbia awarded 1 of first Provocative Questions grants from NCI
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Puzzling question in bacterial immune system answered
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... of the "Micro Market Monitor: North America Perimeter ... http://photos.prnewswire.com/prnh/20130307/600769 The ... at a CAGR of 3.6% from 2014 to 2019. ... this market, Canada is expected ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Clinical Practices (GCP) audit to confirm its adherence ... regulations. This accomplishment enables HITLAB to conduct regulated ... the highest principles for patient safety and research ... global healthcare access, quality, and delivery with innovative ...
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ... 2015-2019"  report to their offering. ... advances in technology. With continuous advances in technology, ... the latest standard that meets the needs and ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... June 13, 2012 To spread public knowledge of ... social media app which allows the general public to ... friends. Available free on iTunes ( http://itunes.apple.com/us/app/autism-quiz/id481913653?mt=8 ), ... for Android. Autism Quiz ...
... publication this week of a "map" of the bacterial make-up ... the ocean. Microbial communities that live on and in ... to have a critical role in human health and disease. ... ambitious Human Microbiome Project (HMP) to define the boundaries of ...
... announces the addition of a significant piece of ... Impact Test System (HITS) recently completed its final ... system is capable of producing horizontal impacts to ... distribution and in-use environments. "With the ...
Cached Biology News:More than 1 way to be healthy: Map of bacterial makeup of humans reveals microbial rare biosphere 2More than 1 way to be healthy: Map of bacterial makeup of humans reveals microbial rare biosphere 3Westpak Deploys Horizontal Impact Test System (HITS) 2
(Date:12/24/2014)... According to Ross Selinger, President of ... Global, the national office market continues to be strong, driven ... evidenced by the third quarter’s surprising 3.9% GDP, unemployment decreasing ... costs have held inflation down and the Fed is keeping ... market remaining soft. , This solid economic news is having ...
(Date:12/24/2014)... 24, 2014 The report expects global ... by 2019. It also provides a carefully analyzed data ... challenges for the market. , Full Copy of Report ... the global market for cell expansion will keep witnessing ... expects this growth to be driven by rapid technological ...
(Date:12/24/2014)... Texas , Dec. 23, 2014 ... company focused on gynecologic disease, announced today that ... Schuler , Birchview Fund LLC and several Vermillion ... of unregistered shares of Vermillion,s common stock and ... stock in a private placement.  ...
(Date:12/24/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ) ... Application (CTA) with the United Kingdom,s ... approval to initiate clinical trials for the continued development ... on the Company receiving CTA regulatory approval, the Company ... the safety, tolerability and dose escalation of Anatabine Citrate ...
Breaking Biology Technology:ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... YORK, Feb. 28, 2012 Organovo, Inc., (OTCQB: ... on using its breakthrough NovoGen 3D human tissue ... research and medical applications, today announced that Keith Murphy, ... March 1st, 2012 TIME:   1:00 PM ...
... Calif., Feb. 28, 2012 Ultragenyx Pharmaceutical Inc., ... rare and ultra-rare genetic disorders, today announced that ... granted orphan drug designation for UX003 for the ... extremely rare autosomal recessive lysosomal storage disorder characterized ...
... Feb. 27, 2012 Ikaria, Inc., a critical care ... critically ill patients, today announced that it has enrolled ... investigating the use of inhaled nitric oxide (iNO) in ... commenced in December 2009, enrolled its last patient six ...
Cached Biology Technology:Organovo, Inc. to Webcast, Live, at RetailInvestorConferences.com on March 1st 2Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7) 2Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7) 3Ikaria® Completes Patient Enrollment in Pivotal Phase III Trial for Bronchopulmonary Dysplasia 2Ikaria® Completes Patient Enrollment in Pivotal Phase III Trial for Bronchopulmonary Dysplasia 3Ikaria® Completes Patient Enrollment in Pivotal Phase III Trial for Bronchopulmonary Dysplasia 4
Mouse monoclonal [TONI-1] to Angiotensin II Type 1 Receptor (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 185 SwissProtID: P30556...
TGF-beta 1,-2,-3 MAb (Clone 1D11)...
HSV-1 gE Envelope Protein (9H3)...
... are functionally defined by their capacity to ... into multiple specialized progenitor cells, which can ... Neural stem cells (NSCs) are capable of ... neurons and oligodendrocytes. During the isolation and ...
Biology Products: